Accelerating Abbvie precision medicine development

Unlocking the power of clinico-genomics to optimize Abbvie’s Immunology pipeline. As Abbvie pushes the boundaries for autoimmune and immunological conditions including Rheumatoid Arthritis, Lupus, IBDs, Helix offers the key to unlocking new insights and accelerating breakthroughs.

Speak to an Expert

GenoSphere™ clinico-genomic datasets

Built on the world's most dynamic precision clinical research network designed to support life science research and optimize therapeutic development. Our data ecosystem combines extensive longitudinal clinical data, cutting-edge Exome+® sequencing from a diverse population, and world-class translational research expertise. This powerful combination enables you to track disease progression with unprecedented precision, uncover rare genetic variants crucial for autoimmune disorders, and rapidly translate genomic discoveries into actionable therapeutic strategies.

Abstarct shapes with blue and other light colors for the background

Rapidly growing and diverse immunology cohort

Helix has curated a clinico-genomic cohort of Exome+® sequencing profiles for 30,000 consented individuals with conditions such as Lupus, Rheumatoid Arthritis (RA), Psoriasis, Multiple Sclerosis (MS), Hashimoto's disease, Crohn's and access to lab results, prescriptions, procedures and much more.

With Helix, you're not just accessing data – you're gaining a competitive edge in developing the next generation of targeted immunology treatments that will transform patients' lives.

Cohort highlights

>2,000

Clinical counts of more >2k consented patients for Lupus, Ulcerative Colitis and Crohn’s disease

>15 types of autoimmune

Including antinuclear antibody (ANA) tests, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and more

>5,000

Clinical count of more than >5k consented patients for Rheumatoid Arthritis

~15yrs lookback

Average patient EHR history: ~15yrs lookback including diagnoses, lab results, prescriptions and much more

Longitudinal Clinical Insights

% of Patients by Age Range: Wide range of adult and geriatric patients across all ages diagnosed with autoimmune conditions with years of look back

Research Insights

Inflammatory Bowel Disease (IBD), including Crohn’s disease and Ulcerative Colitis impacts millions of people in the US. Conventional treatments are currently limited to reducing inflammation, however personalized treatment can offer options to treat the disease directly. Helix scientists recently presented an analysis at the ASHG conference in 2024 on the genetics of Crohn’s disease, and in particular the NOD2 gene where mutations in the gene have been associated with Crohn’s disease and other conditions.

Read the Poster

Key Values for Abbvie’s immunology pipeline:

Identify rare variants, novel drug targets and biomarkers specific for Abbvie’s immunology pipeline

Stratify patient populations for more targeted and efficient clinical trials with consent for recontact in research studies, clinical trials, and surveys.

Use real-world insights to follow the patient journey and monitor treatment responses, adverse events and overall outcomes

Benefit from Helix’s team of experienced genomics and bioinformatics specialists to help translate genetic findings into actionable insights

Additional Resources:

Press Releases

Helix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and Development

Research

Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort

Research

White Paper: Semaglutide and Weight Management

Accelerate Drug Discovery and Development: Partner with Helix

Helix's advanced genomic solutions can transform your R&D efforts, helping you identify novel targets, personalize treatments, and enhance clinical trial design. Our cutting-edge database accelerates your path to market across various therapeutic areas. Fill out the form below to connect with a Helix representative and discover how we can enhance your drug development process.